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ABSTRACT 
 
Introduction: A steep rise in breast cancer cases is anticipated over the coming years in India. Breast cancer in 
India, is the most common cancer among women in the urban areas and ranks second in the rural population. Aims: 
To study the morphological features of breast carcinoma, to identify hormone receptor status and to study the 
relation between morphological features and hormone receptor status. Materials and Methods: This was a 
retrospective and prospective study carried out over a period of two years. A total of 100 cases of carcinoma breast 
were studied for morphological features and their relation to hormone receptor status. Results: The mean age at 
presentation was 50 years and was more common in postmenopausal women, (70 %) cases. Right breast, especially 
the upper outer quadrant was most frequently involved. (52% cases). Most common size of tumor ranged between 2 
to 5cm. Most common histological type of breast carcinoma was invasive ductal carcinoma NOS (not otherwise 
specified) (83.2%). Both premenopausal and postmenopausal cases showed triple negative as the most common 
pattern. Among the invasive ductal carcinoma cases, triple negative was the most common pattern. Most common 
tumor grade in the present study group was grade II and triple negative was the most common pattern in this group. 
Well defined lypmhovascular emboli were present in 16 %, tumor necrosis in 53% of cases and desmoplasia in 60% 
of cases. Only 16% of cases showed infiltration of basal cut margin. Conclusion: Breast cancer cases diagnosed at 
an earlier stage have more favorable prognosis. Increasing the awareness in the public and good programs for early 
detection of the disease will go a long way in reducing breast cancer. 
 
Key words: Breast carcinoma, Immunohistochemistry, Morphology and Triple markers. 
Introduction 
A steep rise in breast cancer cases is anticipated over 
the coming years in India. A 2005 study conducted by 
the international Association of Cancer Research, 
France, projected that India would have 250 000 cases 
of breast cancer by 2015. India reports around 100000 
new cases per year.[1] Breast cancer, in India, is the 
most common cancer among women in the urban areas 
and ranks second in the rural population.[2]At present,  
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the routine histopathology report of breast carcinomas 
is followed by Immunohistochemistry for estrogens 
and progesterone receptor status (ER & PR) and 
Her2/neu markers study. [3]Based on the result of these 
markers, further treatment is planned and the response 
to treatment also depends on the expression of these 
markers. Our aim is to study the morphological 
features of breast carcinoma, identify hormone receptor 
status and to study the relation between morphological 
features and hormone receptor status. 
 
Materials and Methods 
 
This was a retrospective and prospective study carried 
out in the department of Pathology, MNJ Institute of 
Oncology & Regional Cancer Center, and Osmania 
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Medical College, Hyderabad, over a period of two 
years, from September 2010 to September 2012. 
Detailed clinical history was recorded which included 
patient demography, clinical presentation and 
examination findings plus staging investigations. Lab 
investigations, mammography and fine needle 
aspiration cytology reports were also noted when 
available.  
For the prospective cases, specimens were fixed in 
10% buffered formalin for 18-24 hours. The tumor size 
was assessed macroscopically and representative tissue 
bits were processed in automatic processor and paraffin 
blocks were made. For the retrospective cases, formalin 
fixed, paraffin embedded tissue blocks were recovered 
from archives. Routine hematoxylin and Eosin (H & E) 
staining was done for each case and examined for the 
following features: 
a) Histological type of tumors based on 2003 WHO 
classification [4] and grade based on Nottingham 
modification of Scarf-Bloom Richardson 
histological grading system. 
b) Vascular involvement 
c) Lymph node involvement: Number of lymph 
nodes with tumor deposits was noted. 
d) Area of necrosis 
e) Desmoplasia 
f) Status of basal cut margin: Infiltrated or free 
g) Adjacent area changes:  in situ component, 
sclerosing adenosis, fibrocystic disease, 
lymphocytic infiltration  
Estrogen and Progesterone receptor and Her2/neu 
staining technique by IHC: 
DAKO monoclonal mouse antihuman estrogen 
receptor of clone ID5 and PgR 636 were used for 
estrogen and progesterone receptor respectively. 
BIOGENICS monoclonal mouse anti human antibody 
for Her2/neu receptor was used. 
 Allred scoring was used for ER and PR expression. 
Her2/neu [5] was scored on a 0 to 3 scale 
0 - Negative – no staining, 1+ (negative) = faint/ barely 
perceptible partial membrane staining in any 
proportion of tumor cells 
2+ (weak positive)= A weak to moderate complete 
membrane staining of > 10% of tumor cells or strong 
complete membrane staining of < 30% of tumor 
cells.(since FISH technique was not available, 2+ was 
considered as negative.) 
3+ (Strong positive) = A strong complete membrane 
staining in >30% of tumor cells. 
 
Results 
 
A total of 100 cases of breast carcinoma were studied 
with patient age ranging from 22 to 79 years, the mean 
being 50 years. The highest incidence of breast 
carcinoma was found in the age group of 40-49 years 
(37%) and the least incidence was in the age group of < 
30 years (4%). Right breast was involved in 52 cases 
(52%), 47 cases (47%) were from left breast and one 
case (1%) was bilateral. The upper outer quadrant of 
the breast was involved in 56% of all the tumors. 
In 100 cases, ER+ cases were 48 (48%), ER- cases 
were 52 (52%), PR+ cases were 40 (40%) and PR-  
were 60 (60%). Her2 /neu +ve 48 cases (48%) Her 
2/neu–ve 52 cases (52%) 
In the present study, cases were divided into following 
6 groups based on expression of ER, PR and  Her 2/ 
neu expression  
Group 1 ER+/PR+:  33 cases (33%)  
Group 2 ER+/PR-: 15 cases (15%)  
Group 3 ER-/PR+: seven cases (7%). 
Group 4 ER-/PR-: 45 cases (45%)  
Group 5 Her2 neu+: 48 cases (67%)  
Group 6 Her2 neu- : 33 cases (33%)  
 
Table 1: Age wise- ER, PR, Her2/neu positivity 
 
Age (years) No. of cases (%) ER+/PR- ER+/PR-                                ER-/PR+ ER-/PR- HER2/neu+ HER2/neu- 
20-29 4 50 - - 50 50% 50% 
30-39 11 36.36 18.18 - 45 63.63% 36.36% 
40-49 37 21.62 13.51 8 56.75 37.83% 62.16% 
50-59 22 36.36 13.63 18.18 31.81 40.9% 59.09% 
60-69 20 45 25 - 30 60% 40% 
70-79 6 50 - - 50 66.66% 33.33% 
 
In the present study, 70 cases (70%) were 
postmenopausal and 30 (30%) were premenopausal. 
Of the 70 postmenopausal cases, 23 cases( 32.85%) 
were ER+/PR+, 11 cases (15.71%) were ER+/PR-, five 
cases (7%) were ER-/PR+ and 31 cases (44.28%) were  
ER-/PR-. Her 2 neu –ve were 45 (64.28%); Her2 neu 
+ve were 25 (35.71%)Of the 30 premenopausal cases, 
10 cases( 33.33%) were ER+/PR+, 11 cases (15.71%) 
were ER+/PR-, five cases (7%) were ER-/PR+ and 31 
cases (44.28%)  were  ER-/PR-,two cases (6.66%) were 
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ER-/PR+ and 14 cases (46.66%) were ER-/PR-. 16 
cases Her 2 neu -ve (53.30%) ; 14 cases Her2 neu +ve 
(46.6%) 
Tumor size and its relation to ER and PR 
expression: 
Out of 100 cases, eight cases (8%) had tumor size of 
<2 cm in maximum diameter, 82 cases (82%) were 2 
cm to 5 cm and 10 cases (10%) were>5 cm. 
Among the eight cases of breast carcinoma with size 
<2 cm, three cases (37.5%) were ER+/PR+, one case 
(12.5%)  was ER+/PR- and four cases (50%) were ER-
/PR-. 4 cases Her2/ neu + (50%), 4 cases Her2/ neu - 
(50%). 
Among the 82 cases with size between 2cm and 5 cm, 
29 cases (35.36%) were ER+/PR+, 13 cases (15.85%) 
were ER+/PR-,five cases (6%) were ER-/PR+ and 35 
cases (42.68%)were ER-/PR-. 32 cases Her2 /neu + 
(39%), 50 cases Her2 /neu - (60.9%) 
Of the 10 breast carcinoma cases with size > 5 cm, one 
case (10%) was ER+/PR+, one case (10%) was 
ER+/PR-, two cases (20%) were ER-/PR+ and six 
cases (60%) were ER-/PR-.  3 cases Her2/ neu + 
(30%), 7 cases Her2 /neu - (70%). 
Morphology 
Based on morphology , 86 cases (86%) were 
Infiltrative duct cell carcinoma NST (No specific type) 
and the other histological types were two cases (2%) of 
Paget’s disease, three cases (3%) each of Lobular 
carcinoma, and Mixed ductal and lobular carcinoma, 
and one case (1%) each of Intraductal Comedo- 
carcinoma, Cribriform carcinoma, Mucinous 
carcinoma, and Medullary carcinoma. 
Of the 86 Invasive ductal carcinoma NST cases, 26 
cases (30.23%) were ER+/PR+, 13 cases (15.11%) 
were ER+/PR-, seven cases (8%) were ER-/PR+ and 40 
cases (46.51%) were ER-/PR-. Her2/ neu +ve 30 cases 
(34.8%), Her 2/ neu –ve 56 cases (65.11%) 
Both the Paget’s disease cases were triple negative. 
Out of three Lobular carcinomas, two cases (66.66%) 
were ER+/PR+, and one case (33.33%) was ER-/PR-. 3 
cases Her2 /neu +ve (100%) 
All the three cases of papillary carcinoma and one case 
of Intraductal Comedo carcinoma were triple positive. 
Both the cases of mixed ductal and lobular carcinoma 
were ER+/PR-.  
Cribriform carcinoma was ER+/PR+. Her2 /neu 
-ve 
Mucinous and Medullary carcinoma were triple 
negative. 
According to Scarf Bloom Richardson grading, 38 % 
were of grade I, 47 % were grade II and 14 % were 
grade III. 
 
Table 2: Grade wise distributions and Immunohistochemistry Triple Marker Results (99 cases) 
 
Histologic 
Grade 
No of 
Cases 
% ER/PR 
+ 
 
ER+/PR- ER-/PR+ 
 
ER/PR- Her2/neu+ Her2/neu- 
Grade I 38 38 47.3% 18.42% 7.8% 26.3% 55.2% 44.7% 
Grade II 47 47 25.5% 12.7% 6.0% 55.3% 36.1% 63.8% 
Grade III 14 14 14.2% 14.2% 7.0% 64.2% 14.2% 85.7% 
 
Vascular /Perineural involvement  
Out of 100 cases, only 15 cases (15%) showed well 
defined vascular emboli, four cases (4%) showed 
Perineural invasion and a majority of 79 cases (79%) 
did not show well defined vascular involvement in the 
slides studied. Two cases (2%) showed both vascular 
emboli and Perineural involvement. 
Lymph nodal involvement  
Out of the 100 cases, 91 cases were modified radical 
mastectomy (MRM) specimens with identifiable lymph 
nodes, a total of 48 cases (53%) showed tumor deposits 
in the lymph nodes and 43 cases (47%) did not show 
any deposits. 
In nine cases, no lymph nodes were identified. Among 
these, one case was simple mastectomy and eight were 
lumpectomy specimens. 
Tumor necrosis  
Out of the 100 cases, 56 cases (56%) were positive and 
44 cases (44%) were negative for tumor necrosis. 
Desmoplasia 
Out of the 100 cases, 60 cases (60%) showed 
desmoplasia.  
Margin status  
Out of the 100 cases, only 6 cases (16%) showed 
infiltration of the basal cut margin. 
Surrounding breast tissue lesions 
The lesions surrounding the tumor were, Ductal 
carcinoma in situ (DCIS) in 24 cases (24%), 
Fibroadenoma in two cases (2%), Sclerosing adenosis 
in 41 cases (41%), Lymphocytic infiltration in 19 cases 
(19%), Fibrocystic disease (FCD) in15 cases (15%), 
Lobulitis in five cases (15%), Atypical ductal 
hyperplasia (ADH) in six cases (6%), and Atypical 
lobular hyperplasia in three cases (3%). 
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Note: surrounding tissue in some cases showed 
multiple lesions in the same case in different 
combinations. No abnormality was seen in surrounding 
tissue in 12 cases. 
 
Discussion 
 
Breast cancer incidence rates are increasing worldwide. 
In India, it is the most common cancer among women 
in many regions and has overtaken cervical cancer, 
which was the most common cancer a decade ago.[2] 
At present, lot of weightage is given to the predictive 
and prognostic factors in breast carcinoma. The former 
is related to the patient response to a specific therapy, 
while the latter is related to the metastatic potential of 
the tumor. It is important to know the hormone 
receptor status for treatment planning. Especially, the 
status of Her2/neu as its amplification is present in 
approximately 30% of breast cancers and is associated 
with increased disease recurrence. Patients with 
positive Her 2/ neu are amenable to treatment with 
Trastuzumab.[6]Joint ER/PR expression is better in 
identifying breast cancer variants than individual ER or 
PR expression. There may be general agreement 
concerning concordant joint profiles (ER-/PR+ and 
ER-/PR-), but the discordant pair (ER+/PR- & ER-
/PR+) is controversial. 
 
Table 3: Comparison of ER/PR patterns 
 
 ER+/PR+ (%) ER+/PR- (%) ER-/PR+ (%) ER-/PR-(%) 
Nadji et al[7] 3016 (55) 1084 (20) 0 (0) 1397 (25) 
Desai et al[8] 199 (25) 59 (7.4) 167 (21.1) 373 (46.5) 
Vaidyanathan  et al[9] 152 (42.4) 28 (7.8) 16 (4.4) 162 (45.2) 
Dutta et al[10] 10 (13) 13 (18.3) 22 (27.3) 50 (66.6) 
Arpino et al[11] 31415 (57) 13404 (25 ) 1621 (3) 8425 (15) 
Present study 33 (33) 15 (15) 7 (7) 45 (45) 
 
Table 4: Comparison of Her 2 Neu expression 
 
 Her 2 Neu + Her 2 Neu - 
AzizunNisa et al [12] 56 (37.4%) 94 (62.7%) 
Bhagatet al [13] 16 (27.5%) 42 (27.5%) 
Ambroise et al[14] 87 (27.1%) 234 (72.9%) 
Present study 48 (48%) 52 (52%) 
 
In the present study, the most common pattern of 
hormone receptor expression was ER-  /PR- similar to 
Indian studies conducted by Desai et al[8], 
Vaidyanathan et al [9] Dutta et al.[10]and to the study 
of Arpino et al [11]In the present study Her2/neu 
positivity was 48% & negativity was higher, at 52%. 
Different studies [12, 13, 14] were reviewed and 
compared with the present study. All the reference 
studies have shown a definite increase in Her 2/neu 
negativity in the tumors. These negative tumors cannot 
be considered for treatment with Trastuzumab. Studies 
done by Bhagat et al [13] and Ambroiseet al. [14] 
showed percentage of 27.5% and 72.9% Her2/neu 
negativity compared to other studies. Women with 
breast carcinoma who have triple positive tumors live 
longer than women who have triple negative tumors 
because of lesser therapeutic options in the latter group. 
The least common pattern in the present study was 
ER+/ PR- pattern similar to Vaidyanathan et al [9], and 
Arpino et al [11].Although <5% of tumors are ER-
/PR+, these tumors respond to hormone therapy, and 
PR status is predictive of response to hormone 
manipulation. It is felt that PR may be a better indicator 
of endocrine responsiveness than ER alone.[15] Studies 
done by Desai et al[8]and Dutta et al [10] showed 
ER+/PR- and ER+/PR+ as the least common pattern 
respectively. Patients with ER+/PR negative tumors 
respond nearly as well to anastrozole (aromatase 
inhibitor) as those with ER+/PR+ tumors suggests that 
the ER signaling pathway is functional in may 
ER+/PR- tumors, which is due to the PR gene 
regulation via the estrogen pathway.[11] 
 
Age distribution and its relation to ER, PR and Her 
2/neu expression 
 
In the present study, the average age of the cases at 
presentation was 50 years similar to findings of the 
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National Cancer Registry Project (NCRP) network 
during the period of 1994 -98 which reported age range 
from 44.2 years in Dibrugarh to 49.6 years in 
Bangalore and Chennai registries. [16]In contrast, the 
average age of occurrence of breast cancer among US 
white females has been reported to be 61years.[16]In 
Indian population, the incidence begins to rise in the 
early thirties and peaks at 50-64 years. The reasons are 
not clear, but it could be due to under-diagnosis and 
under-reporting amongst the elderly population in 
India.[17] Pillers (1992) combined data on histological 
grading from two centers and found that there was a 
higher frequency of poorly differentiated carcinomas in 
patients aged 34 years and below.[18]In the present 
study, majority of patients were in the age group of 40-
49 years with predominance of 56.75% cases with ER-
/PR negative expression in contrast to study by Grann 
and co-workers [19] which showed 60.5% of ER+/PR+ 
as the predominant hormone receptor expression 
pattern. The triple negative tumors have been 
associated with younger patient ages as well as poorer 
tumor stage and grade.[17]In the present study, cases 
with age below 30 years showed equal incidence of 
ER+/PR+ and ER-/PR- pattern of expression and in age 
group between 30 to 50 years ER-/PR- pattern was 
more common. In our study, highest positivity for 
Her2/neu was noted in the age group of 70-79 with 66-
66% which is indeed a good prognostic factor as these 
patients can be offered Trastuzumab. With increase in 
age, the ER/PR expression pattern showed increase in 
ER+/PR+ cases similar to studies done by Grann et al 
[19]. The age frequency distributions are greatly 
affected by ER/PR statuses as well as by racial/ ethnic 
groups. The ER+PR+ tumors tend to have 2 age peaks, 
one at younger ages ( age peaks of 37-52 years) and 
one at older ages (age peaks of > 65 years).[17]In the 
present study when the ER/PR expression pattern was 
studied in the age group above 60 years, it was noted 
that the incidence of ER-/PR- again increased 
gradually, but sample is too small for generalizing the 
expression pattern.In the present study, incidence of 
ER-/PR+ tumors were seen comparatively in younger 
patients that ER+/PR- cases similar to reports of 
Anderson et al [7]Which is consistent with the 
association of increased ER concentration with ageing 
and increased PR concentration with premenopausal 
status. 
 
Menstrual status and its relation with ER, PR and 
Her2/neu expression  
 
In the present study, 70% of breast carcinoma cases 
were detected in postmenopausal women similar to 
studies done by Anderson et al where it was reported as 
77%. [15]In our study, both premenopausal and 
postmenopausal women showed predominance of ER-
/PR- pattern in contrast to study by Anderson et al 
[15]which showed ER+/PR+ as the predominant 
pattern. Concordant with the present study, persistence 
of ER-/PR- pattern was also found in the menopausal 
age group in study by Dutta et al.[10]Among the 
postmenopausal women, the incidence of ER+/PR- 
cases and among the premenopausal women, the 
incidence of ER-/PR+ cases were higher, similar to 
Anderson et al study respectively.[15]In the present 
study Her 2 neu negativity is observed in both 
premenopausal and post menopausal women with a 
percent of 53.3% % 64.28% respectively. The findings 
are similar to the reference study by Zheng W et 
al[20]which also showed Her2 Neu negativity in pre-
menopausal and post- menopausal women as27.4% and 
24.8% respectively.  In the reference study Her 2/ neu 
positivity pattern is close relatively in both 
premenopausal and post menopausal women. Present 
study showed predominant involvement of the right 
breast (52%) which is similar to the study done by 
Saleh. [21]where it was reported as 53. 6 %. 
  
Tumor size and its relation to ER, PR and Her 2 
/neu expression 
 
In the present study, in majority of cases the tumor size 
ranged between 2 and 5 cm similar to studies by 
Azizun-Nisa et al [12] and Saleh et al [21]. 
 
 
Table 5: Comparison of tumor size distribution 
 
Tumor size (cm) Farid Salah et al [21] (%) Azizun-Nisa et al[12] (%) Present study n(%)100cases 
< 2 25 (15.1) 18 (12) 8 (8) 
2-5 89 (53.6) 79 (52.7) 82 (82) 
> 5 52 (31.3) 53 (35.3) 10 (10) 
 
In the present study, the least common tumor size was 
<2 cm similar to studies done by Saleh et al.[21] and 
Azizun-Nisa et al [12], but the incidence of tumors 
with size >5 cm was comparatively higher in their 
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studies than the present study. Breast cancer patients of 
Indian origin tend to be younger, with high grade, 
larger tumors as compared to western series.[22] 
 
Comparison of tumor size and Her2 /neu status 
 
In the present study there is predominant Her2 /neu 
negativity in all the size groups in concordance with 
the reference study by Azizun-Nisa et al.[12] 
 
Tumor type and its relation to ER, PR and Her 
2/neu expression 
 
In our study, the most common histological type was 
invasive ductal carcinoma similar to studies done by 
Saleh et al [21].  Histology as a prognostic factor has 
been well documented. Invasive ductal carcinoma 
(NST) has a poor survival compared to other types.[16] 
In the present study, among the invasive ductal 
carcinoma cases, ER-/PR- was the most common 
pattern, similar to Indian study done by Kaul et al[22], 
but is in contrast to studies done by Dunnwald et al 
[23].. Grann et al [19] which showed ER+PR+ as the 
most common pattern. The high frequency of positive 
ER in invasive lobular carcinoma may reflect a special 
selective sensitivity of this distal segment of the duct to 
estrogens and other hormones. In the present study, 
ductal carcinoma showed a predominant Her2 /neu 
negative pattern in about 65.11% which is similar to 
the study by Hoff et al [24] which showed negativity in 
60 %. In contrast to the ductal carcinoma, the lobular 
and mixed variants showed a predominant Her2 /neu 
positivity with about 100% and 100% respectively in 
the present study. This is similar to the study by Hoff et 
al[24] which showed 97% & 96% positivity 
respectively. 
 
Tumor grade and its relation with ER, PR and 
Her2/ neu expression 
 
In the present study, the most common tumor grade 
was grade II (47%) similar to studies by Yamashita et 
al(57%), [25]  Dutta el al(76%).[10] The least common 
was grade III in contrast to grade I in both Yamashita 
et al[25]  and Dutta et al. [10]   In the present study the 
Her2/neu negativity increased from Grade I to III 
which compares well with the study of Azizun- Nisa et 
al [12]In the present study, grade I tumors showed 
predominance of positive ER and PR expression 
similar to studies done by Saleh et al [21] and Azizun-
nisa et al [12].  Similar association of ER positivity 
with low grade tumors was shown by Rosen et 
al.[26]In the present study among the grade II tumors, 
negative ER and PR expression was predominant 
similar to studies done by Saleh et al [21], Kaul et 
al[22] and Azizun- Nisa et al. [12]Among the grade III 
tumors, negative ER expression was predominant type 
and correlated well with studies done by Saleh et al 
[21],  Peiro et al [27] and Azizun- Nisa et al [12], but 
negative PR expression showed predominance in the 
present study in contrast to Saleh et al [21] and Azizun 
–Nisa et al [12] studies. High grade tumors are likely to 
have more lymph nodal metastases, recurrences and 
metastasis related deaths.[28] 
 
Lymphovascular/Perineural involvement  
 
In our study, only 16% cases showed vascular emboli 
in contrast to 31.4 % reported by Peiro et al [27]where 
210 cases were studied. The incidence of blood vessel 
invasion ranges from under 5% to almost 50%. This is 
due to variety of factors including patient population, 
the criteria and methodology used and difficulty in 
identifying blood vessels.Vascular invasion correlates 
with grade of the tumor, tumor size and lymph nodal 
status.[28] 
 
Lymph nodal involvement  
 
In the present study, a majority of 53% cases showed 
axillary lymph nodal involvement similar to studies by 
Azizun-Nisa et al [12] and Ahmad et al [28]. In 
contrast, the study done by Lisa et al [23] showed only 
37% of lymph nodal involvement. 
The survival rate also depends upon the level of the 
axillary node involved (low, medium or high), the 
absolute number (fewer than4, versus 4 or more) the 
amount of metastatic tumor and the presence or 
absence of extra nodal spread.[29] 
 
Tumor necrosis  
 
In the present study, 56% of cases showed tumor 
necrosis in contrast to only 37% of cases in Peiro et al 
[27 ] study. But similar to our study a higher proportion 
of tumor necrosis was noted in Azizun-nisa et al study 
(70%).[12] Extensive tumor necrosis is associated with 
an aggressive clinical course and decreased survival 
rates. [28] 
 
Desmoplasia 
 
Desmoplasia, is a poorly understood phenomenon often 
associated with invasive carcinoma.It is regarded as a 
host reaction to the invasive tumor.  In the present 
study, only 60% of cases showed desmoplasia in 
contrast to 94% in Azizun-Nsa et al [12] study. 
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Margin status  
 
In the present study, 16% of cases showed microscopic 
involvement of basal resected margin. Tumor margins 
often represent a reliable source of positive or negative 
disease outcome.[21] 
In the present study, the most common associated 
lesions in the surrounding breast tissue were selerosing 
adenosis and fibrocystic disease (FCD).The intensity of 
the lymphoid and plasmacytic reaction in or around a 
primary mammary carcinoma represents an 
immunological reaction to tumor antigens.  
 
Conclusion 
 
The high proportion of receptor negative cases can be 
partially explained by the younger age of our patients 
or due to real racial differences. Due to differences in 
genotype, phenotype, lifestyle, socio-demographic 
structure and ethnicity, the presentation and behavior 
of breast cancer in India may be different [22].It is well 
known that breast cancer cases diagnosed at an earlier 
stage have more favorable prognosis. Increasing the 
awareness in the public and good programs for early 
detection of the disease will go a long way in reducing 
breast cancer. 
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